Heidi Overton FDA Nomination Advances Amid Vaccine Scrutiny

The Senate Health, Education, Labor and Pensions committee will vote on whether to advance Dr. Heidi Overton's nomination to be FDA commissioner to the full Senate. President Trump's nominee, who would oversee about 16,000 staffers, appeared before the committee on Thursday.

Overton's background and qualifications

Dr. Heidi Overton, 37, would be one of the youngest people ever to lead the agency. She is board-certified in public health and general preventive medicine. Overton graduated from the University of New Mexico School of Medicine, was a surgical resident at Johns Hopkins University, and finished her Ph.D. In clinical investigation at the Johns Hopkins Bloomberg School of Public Health.

She brings political experience from the Trump administration. Overton joined Trump's first administration as a White House fellow on the Domestic Policy Council during the Covid-19 pandemic. She has been a deputy assistant for domestic policy in the second Trump administration, overseeing health initiatives for the White House. Prior to that, she was chief policy officer and vice chair of the America First Policy Institute's Center for a Healthy America. Dr. Overton lives with type 1 diabetes, an autoimmune condition.

Vaccine policy under scrutiny

Questioning focused sharply on vaccine policy. Senator Bill Cassidy, a Republican doctor from Louisiana, asked if any vaccines on the U.S. Market are unsafe. Overton stated every vaccine currently marketed is safe and effective according to FDA standards. She specifically countered claims by Trump that the MMR vaccine is lethal, calling it safe, effective, and "our best tool right now in the public health response to the measles outbreak."

Cassidy questioned Overton about her involvement in Trump's executive order on vaccines. That order aims to scale back routine childhood vaccinations and prioritizes splitting the MMR vaccine into individual components to be given at separate visits. Experts warn splitting the vaccine would decrease uptake and worsen measles cases, which are at their highest level in the US since the disease was declared eliminated decades ago.

When asked what she would do if the president asked her to act against science, Overton said she would give him her best advice and follow statutory requirements for safety and efficacy determinations.

Food safety and mifepristone oversight

Food safety and the abortion pill mifepristone also drew intense scrutiny. Senator Bernie Sanders, an independent from Vermont, noted the number of FDA food facility inspections conducted overseas is down by more than 35% compared to 2019. Overton said she is committed to ensuring every food safety review meets the highest standard with accurate communication.

On mifepristone, senators presented conflicting views. Democrat Tammy Baldwin laid out safety data, while Republican Josh Hawley argued the drug is unsafe. Overton affirmed mifepristone has been approved by the FDA with appropriate risk evaluation strategies. She said a current internal safety study is ongoing and very important, and there has been no change to the drug's label. If confirmed, she said her most urgent task would be to get briefed on that review's status.

Bioethicist Arthur L. Caplan, PhD, said mifepristone has been proven unequivocally safe as one of the most reviewed drugs of all time. He argued the only reason its safety is being questioned is the politics of abortion. Caplan also blamed FDA surveillance and staffing issues for food safety problems.

Agency leadership and advisory role

Questions about political influence extended to advisory committees. Senator Chris Murphy, a Democrat from Connecticut, asked about the politicization of the agency and its advisory boards. Overton pledged not to shut down any advisory committees but to review them to ensure they fulfill their highest purpose. She called the committees a key part of the FDA's administrative record.

Caplan was critical of Overton's hearing performance regarding political pressure. "She was not strong enough," he said. She basically gave us what I would call a PR-shaped response.

The nomination proceeds as the agency seeks stable leadership. The previous commissioner, Dr. Martin Makary, resigned in May, and Kyle Diamantas repeatedly turned down the position. The Senate Health, Education, Labor and Pensions committee will vote on whether to advance Dr. Heidi Overton's nomination to the full Senate.